Nordicus Partners Corp. (NORD)
Investor overview
Nordicus Partners is the only publicly traded U.S. business accelerator and holding company focused exclusively on empowering Nordic life sciences companies to succeed in the U.S. market. By combining Nordic scientific innovation with U.S. operational expertise, Nordicus targets transformative, scalable opportunities in high-growth life sciences with unmet medical needs. Current portfolio companies include Orocidin who is developing treatments against aggressive periodontal disease, and Bio-Convert who is focused on preventing oral leukoplakia, a potentially cancerous lesion in the mouth.
Why Invest?
-
Portfolio Diversification Strategy:
Nordicus’ balanced portfolio positions us as a stable and resilient company, mitigating risk with significant upside potential.
-
High-Growth Focus:
Targeting life sciences markets with significant unmet medical needs.
-
Business Strategy:
A clear 4-step process (Scout, Accelerate, Acquire, Exit)
-
Experienced Leadership:
A seasoned team combining Nordic innovation with U.S. market expertise to identify and scale high-potential ventures.
-
Financial Upside:
Portfolio valuations suggest strong potential, leveraging all stock acquisitions to scale effectively.
-
Competitive Edge:
A dual-market approach and expertise in reviving stalled drug candidates, positioning Nordicus uniquely for success.
In The Press
Navigating Corporate Finance in the Life Sciences Sector
Contact
Media Inquiries:
Ulveman & Børsting
Copenhagen, Denmark
Tel: +45 31 906 900
Mail: Kontakt@ulvemanborsting.com
Transfer Agent:
Transfer Online, Inc.
512 SE Salmon St.
Portland, OR 97214
Tel:+1 503-227-2950
Mail: info@transferonline.com
Investor
FAQs
US Office
Nordicus Partners Corp. resides at 280 S. Beverly Drive, Suite 505, Beverly Hills, CA 90212.
DK Office
C/O NP Bioinnovation A/S
Address: Vandtårnsvej 62A, 1. E, DK-2860 Søborg, Denmark.
Nordicus Partners Corp. was founded in 1993 under its original Company name; Cardiotech International, Inc.
Nordicus Partners Corporation is a U.S. publicly traded business accelerator and holding company focused exclusively on empowering Nordic life sciences companies to succeed in the U.S. market.
Nordicus Partners Corp. went public in 1993 under its original name Cardiotech International, Inc. Mitsubishi Chemical Performance Polymers acquired AdvanSource Biomaterials Corporation (formerly Cardiotech International, Inc.) on January 31, 2020, which led to the company becoming a shell company with no operational activity. Conversely, the company changed its name to EKIMAS Corporation and later became Nordicus Partners Corp. as we know it today.
Nordicus Partners Corp. is currently listed on the OTCQB Market, with the ticker symbol "NORD".
Nordicus Partners Corp. fiscal year ends on March 31.
Please contact a stockbroker, bank, or other institution that offers brokerage services to buy or sell Nordicus Partners Corp. common stock.
Please contact our Investor Relations department, using our contact form.
Nordicus Partners Corp. transfer agent is Transfer Online, Inc. They can be reached at the following addresses:
Website: https://transferonline.com/
E-mail inquiries: info@transferonline.com
Transfer Online, Inc.
512 SE Salmon St.
Portland, OR 97214
Please contact our transfer agent, Transfer Online, Inc., to make changes.
Within 45 days after our quarter ends, a 10-Q will be filed with the SEC and within 90 days after our fiscal year end, a 10-K will be filed with the SEC.
Nordicus Partners Corp. does not currently pay dividends.
Nordicus Partners Corp. independent registered public accounting firms is Fruci & Associates II, PLLC
Our legal counsel is Lucosky Brookman LLP
All SEC filings can be accessed directly from the SEC, here.
Nordicus Partners Corp. Investor Relations department can provide information regarding financial performance and business strategy that is already made public.
You can contact Investor Relations through our contact page here.